aTYR PHARMA INC - 8-K Filing
aTyr Pharma filed an 8-K to disclose a corporate presentation dated June 2026, outlining its strategic focus on developing therapies based on tRNA synthetase biology for inflammatory and fibrotic diseases. The company highlighted efzofitimod in Phase 3 trials for pulmonary sarcoidosis after completing the EFZO-FIT trial with insights used to refine future study design. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ATYR